갑상선유두암에서 p53과 Cyclin D1의 발현이 가지는 예후인자로서의 의미
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 석재연 | - |
dc.contributor.author | 정동해 | - |
dc.contributor.author | 정유승 | - |
dc.contributor.author | 류정원 | - |
dc.contributor.author | 이영돈 | - |
dc.date.available | 2020-02-28T13:44:15Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2015-06 | - |
dc.identifier.issn | 2508-8149 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/11539 | - |
dc.description.abstract | Purpose: P53 and cyclin D1 have been evaluated as a prognostic marker in papillary thyroid carcinoma (PTC). However, the relationship between p53/cyclin D1 and PTC prognosis has not yet been confirmed. Therefore, we investigated the relationship between p53/cyclin D1 and PTC prognostic factors.Methods: 919 patients with PTC were enrolled. Immunohistochemistry slides were reviewed for p53 and cyclin D1 immunoreactivity. Patients were classified into two groups according to the p53 and cyclin D1 grade: negative for ≤5% and positive for >5%. Medical records were reviewed to evaluate the prognostic factors, lymph node metastatic ratio (LNMR), and MACIS score. We analyzed patients based on p53/cyclin D1(−/−), p53/cyclin D1(−/+), p53/cyclin D1(+/−), p53/cyclin D1(+/+) separately for evaluation of independent effect of p53 and cyclin D1.Results: Mean age of the patients was 49.73 years (range 15∼87), and tumor size was 1.19 cm (range 0.1∼5.0). P53 was positive in 809 (88.0%) and cyclin D1 was positive in 748 (81.4%). Positivity of p53 and cyclin D1 were correlated (r=0.448). There was no statistical significance in MACIS score. Positivity of p53 and cyclin D1 were related with larger tumor size, older age, early T stage, more tumor capsulation, and female. LNMR was higher in p53/cyclin D1(+/−) than p53/cyclin D1(−/−) (P=0.036), p53/cyclin D1(−/+) than p53/cyclin D1(−/−) (P=0.034), and p53/cyclin D1(+/+) than p53/cyclin D1(−/−) (P=0.007). Conclusion: There was no consistent relationship between p53/cyclin D1 and worse prognostic factors of PTC. However, LNMR was higher in p53(+) and cyclin D1(+) cases independently, much more in p53/cyclin D1(+/+) than p53/cyclin D1(−/−). | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한갑상선-내분비외과학회 | - |
dc.relation.isPartOf | The Journal of Endocrine Surgery | - |
dc.title | 갑상선유두암에서 p53과 Cyclin D1의 발현이 가지는 예후인자로서의 의미 | - |
dc.title.alternative | Prognostic Value of p53 and Cyclin D1 in Papillary Thyroid Carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.bibliographicCitation | The Journal of Endocrine Surgery, v.15, no.2, pp.25 - 33 | - |
dc.identifier.kciid | ART001998942 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 33 | - |
dc.citation.startPage | 25 | - |
dc.citation.title | The Journal of Endocrine Surgery | - |
dc.citation.volume | 15 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | 석재연 | - |
dc.contributor.affiliatedAuthor | 정동해 | - |
dc.contributor.affiliatedAuthor | 정유승 | - |
dc.contributor.affiliatedAuthor | 류정원 | - |
dc.contributor.affiliatedAuthor | 이영돈 | - |
dc.subject.keywordAuthor | 갑상선유두암 | - |
dc.subject.keywordAuthor | p53 | - |
dc.subject.keywordAuthor | Cyclin D1 | - |
dc.subject.keywordAuthor | 예후 | - |
dc.subject.keywordAuthor | 림프절 전이율 | - |
dc.subject.keywordAuthor | Papillary thyroid carcinoma | - |
dc.subject.keywordAuthor | p53 | - |
dc.subject.keywordAuthor | Cyclin D1 | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Lymph node metasta-tic ratio | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.